Abstract
Reecha Sofat and colleagues argue that prescribing advice needs updating in the light of recent evidence that all classes of blood pressure lowering drugs are broadly equivalent
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adrenergic beta-Antagonists / therapeutic use
-
Age Factors
-
Angiotensin Receptor Antagonists / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Antihypertensive Agents / therapeutic use*
-
Calcium Channel Blockers / therapeutic use
-
Clinical Trials as Topic
-
Diabetes Mellitus, Type 2 / etiology
-
Diuretics / therapeutic use
-
Humans
-
Hypertension / drug therapy*
-
Practice Guidelines as Topic*
-
Practice Patterns, Physicians' / statistics & numerical data*
-
Renin-Angiotensin System / drug effects
-
Risk Factors
-
United Kingdom
Substances
-
Adrenergic beta-Antagonists
-
Angiotensin Receptor Antagonists
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents
-
Calcium Channel Blockers
-
Diuretics